Reducing the hidden burden of severe asthma: recognition and referrals from primary practice

References

• Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, Tran TN. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. JAA. 2018;11(11):193–204. doi:10.2147/JAA.S176026.
   Google Scholar
• Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term OCS therapy and its side effects in severe asthma in adults - A focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703. doi:10.1183/13993003.00703-2018.
   PubMed Web of Science ®Google Scholar
• Global Initiative in Asthma. Diagnosis and management of difficult-to-treat and severe asthma. Available from http://ginasthma.org/gina-reports/ [last accessed on 23 September 2019].
   Google Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Trevor JL, Chipps BE. Severe Asthma in Primary Care: Identification and Management. Am J Med. 2018;131(5):484–491. doi:10.1016/j.amjmed.2017.12.034.
   PubMed Web of Science ®Google Scholar
• World Allergy Organization (WAO). Economic Analysis of the Cost of Treatments for Severe Asthma. Available from: http://www.worldallergy.org/educational_programs/world_allergy_forum/anaheim2005/blaiss.php [last accessed 15 March 2019].
   Google Scholar
• Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1. doi:10.1186/s40733-016-0029-3.
   PubMedGoogle Scholar
• Chipps BE, Bacharier LB, Farrar JR, Jackson DJ, Murphy KR, Phipatanakul W, Szefler SJ, Teague WG, Zeiger RS. The pediatric asthma yardstick: Practical recommendations for a sustained step-up in asthma therapy for children with inadequately controlled asthma. Ann Allergy Asthma Immunol. 2018;120(6):559–579. doi:10.1016/j.anai.2018.04.002.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Wechsler ME. Severe asthma and the primary care provider: identifying patients and coordinating multidisciplinary care. Am J Med. 2017;130(12):1479. doi:10.1016/j.amjmed.2017.10.001.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Busse WW, Pedersen S, Tan WC, Chen Y-Z, Jorup C, Lythgoe D, O'Byrne PM. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017;389(10065):157–166. doi:10.1016/S0140-6736(16)31399-X.
   PubMed Web of Science ®Google Scholar
• Similowski T, Suissa S. Systemic steroids in severe forms of COPD exacerbations: a question of balance?. Eur Respir J. 2014;43(3):668–670. doi:10.1183/09031936.00000214.
   PubMed Web of Science ®Google Scholar
• Rowe BH, Keller JL, Oxman AD. Effectiveness of steroid therapy in acute exacerbations of asthma: a meta-analysis. Am J Emerg Med. 1992;10(4):301–310. doi:10.1016/0735-6757(92)90007-K.
   PubMed Web of Science ®Google Scholar
• Price D, Bjermer L, Bergin DA, Martinez R. Asthma referrals: a key component of asthma management that needs to be addressed. JAA. 2017;10:209–223. doi:10.2147/JAA.S134300.
   Google Scholar
• Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332–336. doi:10.1056/NEJM200008033430504.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Chiu G. Perceptions of asthma control in the United Kingdom: a cross-sectional study comparing patient and healthcare professionals' perceptions of asthma control with validated ACT scores. NPJ Prim Care Respir Med. 2017;27(1):48. doi:10.1038/s41533-017-0050-x.
   PubMed Web of Science ®Google Scholar
• Bidad N, Barnes N, Griffiths C, Horne R. Understanding patients’ perceptions of asthma control: a qualitative study. Eur Respir J. 2018;51(6):1701346. doi:10.1183/13993003.01346-2017.
   PubMed Web of Science ®Google Scholar
• Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Asthma. Lancet. 2018;391(10122):783–800. doi:10.1016/S0140-6736(17)33311-1.
   PubMed Web of Science ®Google Scholar
• Heffler E, Madeira LNG, Ferrando M, Puggioni F, Racca F, Malvezzi L, Passalacqua G, Canonica GW. Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma. J Allergy Clin Immunol Pract. 2018;6(3):776–781. doi:10.1016/j.jaip.2018.01.025.
   PubMed Web of Science ®Google Scholar
• Brode SK, Campitelli MA, Kwong JC, Lu H, Marchand-Austin A, Gershon AS, Jamieson FB, Marras TK. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J. 2017;50(3):1700037. doi:10.1183/13993003.00037-2017.
   PubMed Web of Science ®Google Scholar
• Miloslavsky EM, Naden RP, Bijlsma JW, Brogan PA, Brown ES, Brunetta P, Buttgereit F, Choi HK, DiCaire JF, Gelfand JM, et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76(3):543–546. doi:10.1136/annrheumdis-2016-210002.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141(1):110–116. doi:10.1016/j.jaci.2017.04.009.
   PubMed Web of Science ®Google Scholar
• Hossny E, Rosario N, Lee BW, Singh M, El-Ghoneimy D, Soh JY, Le Souef P. The use of inhaled corticosteroids in pediatric asthma: update. World Allergy Organ J. 2016;9:26. doi:10.1186/s40413-016-0117-0.
   PubMed Web of Science ®Google Scholar
• Gray N, Howard A, Zhu J, Feldman LY, To T. Association Between Inhaled Corticosteroid Use and Bone Fracture in Children With Asthma. JAMA Pediatr. 2018;172(1):57–64. doi:10.1001/jamapediatrics.2017.3579.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Calabrese C, Terracciano R, de Blasio F, Vatrella A, Pelaia G. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Ther Adv Respir Dis. 2018;12:175346661881019. 1753466618810192. doi:10.1177/1753466618810192.
   Web of Science ®Google Scholar
• Incorvaia C, Mauro M, Makri E, Leo G, Ridolo E. Two decades with omalizumab: what we still have to learn. BTT. 2018;12:135–142. doi:10.2147/BTT.S180846.
   Google Scholar
• Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, Iribarren C, Chen H, Carrigan G, Rosen K, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560–567. doi:10.1016/j.jaci.2014.02.007.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkstrom V, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8.
   PubMed Web of Science ®Google Scholar
• Murphy K, Jacobs J, Bjermer L, Fahrenholz JM, Shalit Y, Garin M, Zangrilli J, Castro M. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2017;5(6):1572–1581. doi:10.1016/j.jaip.2017.08.024.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092.
   PubMed Web of Science ®Google Scholar
• Heaney LG, McGarvey LP. Personalised Medicine for Asthma and Chronic Obstructive Pulmonary Disease. Respiration. 2017;93(3):153–61. doi:10.1159/000455395.
   PubMed Web of Science ®Google Scholar
• Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. JAA. 2017;10:47–56. doi:10.2147/JAA.S121276.
   Google Scholar
• Smith JR, Noble MJ, Musgrave S, Murdoch J, Price GM, Barton GR, Windley J, Holland R, Harrison BD, Howe A, et al. The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax. 2012;67(12):1052–1060. doi:10.1136/thoraxjnl-2012-202093.
   PubMed Web of Science ®Google Scholar